• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Labcorp Holdings Inc.

    5/29/25 4:05:23 PM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    S-8 POS 1 d856036ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on May 29, 2025

    Registration No. 333-279514

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-8

    REGISTRATION STATEMENT (333-279514)

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Labcorp Holdings Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   99-2588107

    (State or other jurisdiction of

    incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    358 South Main Street, Burlington, North Carolina   27215
    (Address of Principal Executive Offices)   (Zip Code)

    Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan

    (Full titles of the plans)

    Sandra D. van der Vaart

    Executive Vice President, Chief Legal Officer and Corporate Secretary

    Labcorp Holdings Inc.

    358 South Main Street

    Burlington, North Carolina 27215

    (Name and address of agent for service)

    (336) 229-1127

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William I. Intner

    Hogan Lovells US LLP

    100 International Drive, Suite 2000

    Baltimore, Maryland 21202

    (410) 659-2700

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment No. 1”) relates to the Registration Statement on Form S-8 (File No. 333-279514) (the “Registration Statement”) filed with the Securities and Exchange Commission by Labcorp Holdings Inc. (the “Company”) and is being filed to deregister only those shares of the Company’s common stock, par value $0.10 per share (“Common Stock”), issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan (the “Plan”) that were registered under the Registration Statement and remain unissued or unsold thereunder.

    The Company is no longer offering its securities under the Plan. Thus, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, the Company hereby removes from registration any shares of Common Stock registered under the Registration Statement issuable pursuant to the Plan which remain unissued or unsold as of May 15, 2025. Although any shares of Common Stock issuable pursuant to the Plan are being deregistered, this Post-Effective Amendment No. 1 shall not serve to reduce the number of shares of Common Stock covered by the Registration Statement and issuable pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, State of North Carolina, on May 29, 2025.

     

    LABCORP HOLDINGS INC.
    By:  

    /s/ Sandra D. van der Vaart

      Sandra D. van der Vaart
      Executive Vice President, Chief Legal Officer and Corporate Secretary

    No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    SEC Filings

    View All

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    2/9/26 1:30:58 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    2/9/26 8:34:53 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    1/29/26 4:15:36 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

    Elecsys® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathologyNow available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive declineExpands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settingsBURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessme

    2/11/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kong Garheng

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/12/26 11:28:09 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Rothman Paul

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/12/26 11:24:01 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Sampson John H

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    2/12/26 11:09:48 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

    TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear

    1/8/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care